CSI Market
Sign In | Register

Monopar Therapeutics Inc (MNPR) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access MNPR quarterly Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Monopar Therapeutics Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-13.72
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation4.84
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Stock Based Compensation Expense Non Cash-
Other Income From Ppp Loans Forgiveness-
Other Currents Assets-
Increase Decrease In Inprocess Research And Development Accrued Expenses-0.01
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.39
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital0.02
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.72
Discontinued operations0.00
Net Cash flow from Operating Activities-12.20
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds-63.45
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-63.45
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-34.43
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-1.13
Common Stock Issuance Costs-
Proceeds From Exercise Of Stock Options-
Increase Decrease Deferred Offering Costs-
Payments Of Offering Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Accrued But Unpaid Initial Public Offering Costs-
Taxes Paid Related To Net Share Settlement Of Vested Restricted Stock Units-
Ppp Forgivable Bank Loan-
Payments For Other Offering Costs-
Exercise Of Stock Options-
Proceeds From Issuance Public Offering-
Proceeds From Issuance Public Offering And Private Placement127.14
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities91.57
Effect of exchange rate on cash flow0.10
Discontinued operations0.00
Free Cash Flow-12.20
Total Cash Flow16.02
4 historic quarters locked

Sign in to unlock the full Monopar Therapeutics Inc cash flow history.

Sign In Create Free Account

About Monopar Therapeutics Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-26-010025

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License